Images

Filter by

Table 2 Invasive Therapies for the Management of Hypertrophic Cardiomyopathy With Obstructive Physiology and Studied Outcomes
Table 2: Invasive Therapies for the Management of Hypertrophic Cardiomyopathy With Obstructive Physiology and Studied Outcomes
Table 1 Pharmacological Therapies for Hypertrophic Cardiomyopathy with Obstructive Physiology and Studied Outcomes
Table 1: Pharmacological Therapies for Hypertrophic Cardiomyopathy with Obstructive Physiology and Studied Outcomes
Figure 1 Pharmacological Management of Hypertrophic Cardiomyopathy With Obstructive Physiology
Figure 1: Pharmacological Management of Hypertrophic Cardiomyopathy With Obstructive Physiology
Table 2 Comparison of Current and Investigational Therapies for Transthyretin Amyloidosis Dosing Route of Administration and Regulatory Status
Table 2: Comparison of Current and Investigational Therapies for Transthyretin Amyloidosis: Dosing, Route of Administration, and Regulatory Status
Table 1 Baseline Demographics and Clinical Characteristics of Participants in Key ATTR CM Clinical Trials
Table 1: Baseline Demographics and Clinical Characteristics of Participants in Key ATTR-CM Clinical Trials
Figure 1 Mechanisms of Action for Transthyretin Amyloid Cardiomyopathy Therapies
Figure 1: Mechanisms of Action for Transthyretin Amyloid Cardiomyopathy Therapies
Table 5 Prevalence of Malnutrition and 1 year All cause Mortality in Patients with CHF stratified by BMI suPAR and hsCRP
Table 5: Prevalence of Malnutrition and 1-year All-cause Mortality in Patients with CHF, stratified by BMI, suPAR and hsCRP
Table 4 Cox Regression 1 year Survival Analysis Stratified by Nutritional Status and BMI
Table 4: Cox Regression 1-year Survival Analysis Stratified by Nutritional Status and BMI
Table 3 Post discharge Death† in Elderly Patients with Chronic Heart Failure Nutritional Indices and Selected Biomarkers
Table 3: Post-discharge Death† in Elderly Patients with Chronic Heart Failure: Nutritional Indices and Selected Biomarkers
Table 2 All cause Mortality† in Elderly Patients with Chronic Heart Failure Nutritional Indices and Selected Biomarkers
Table 2: All-cause Mortality† in Elderly Patients with Chronic Heart Failure: Nutritional Indices and Selected Biomarkers
Figure 2 Receiver Operating Characteristic Curves for Predicting 1 Year Mortality in Elderly Patients ≥65 years with Chronic Heart Failure
Figure 2: Receiver Operating Characteristic Curves for Predicting 1-Year Mortality in Elderly Patients (≥65 years) with Chronic Heart Failure
Figure 1 One year Survival Analysis in Elderly Patients ≥65 years with Chronic Heart Failure Stratified by Nutritional Status
Figure 1: One-year Survival Analysis in Elderly Patients (≥65 years) with Chronic Heart Failure Stratified by Nutritional Status